Literature DB >> 32093587

Incidence and Mortality of Myocardial Infarction and Stroke in Patients with Hyperthyroidism: A Nationwide Cohort Study in Korea.

Hyun Jung Kim1, Taeuk Kang2, Min Ji Kang3, Hyeong Sik Ahn1, Seo Young Sohn4.   

Abstract

Background: Hyperthyroidism is associated with various cardiovascular risk factors. However, the relationship between hyperthyroidism and myocardial infarction (MI) or stroke has not been fully elucidated; only a few studies have investigated the association of hyperthyroidism with survival after MI or stroke.
Methods: We included 59,021 hyperthyroid patients and a control cohort with 1,180,420 age- and sex-matched subjects from the Korean National Health Insurance database. Blood pressure, body mass index (BMI), glucose and cholesterol levels, and smoking history were obtained during National Health screening examination. We compared the incidence of MI, stroke, and survival after cardiovascular events between subjects with hyperthyroidism and the control cohort.
Results: Subjects with hyperthyroidism had higher blood pressure, fasting glucose, and smoking rate, but lower cholesterol levels and a lower obesity rate compared with the control cohort. After adjusting these differences, as well as atrial fibrillation, hyperthyroidism was associated with increased risk of MI and ischemic stroke. Adjusted hazard ratios (HRs) for MI and ischemic stroke with hyperthyroidism was 1.16 [95% confidence interval, CI 1.03-1.30] and 1.12 [CI 1.04-1.20], respectively. In age-, sex-, and BMI-stratified analyses, an increased risk of MI and ischemic stroke remained significant in females, the older age group (≥50 years), and nonobese subjects (BMI <25 kg/m2), but not in males, the younger age group (<50 years), and obese subjects (BMI ≥25 kg/m2). The risk of hemorrhagic stroke was not different between subjects with hyperthyroidism and controls. Adjusted HRs for mortality in subjects with hyperthyroidism who developed MI, ischemic stroke, and hemorrhagic stroke were 1.11 ([CI 0.86-1.43], p = 0.44), 0.89 ([CI 0.75-1.05], p = 0.16), and 1.13 ([CI 0.88-1.47], p = 0.34), respectively. Conclusions: Hyperthyroidism is associated with increased risk of MI and ischemic stroke, independent of cardiovascular risk factors. This association is prominent in subjects with age ≥50 years, in females, and in the nonobese group. Hyperthyroidism did not significantly affect the mortality secondary to cardiovascular events.

Entities:  

Keywords:  hyperthyroidism; mortality; myocardial infarction; stroke

Mesh:

Year:  2020        PMID: 32093587     DOI: 10.1089/thy.2019.0543

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  14 in total

Review 1.  Purinergic signaling in thyroid disease.

Authors:  Ying Le; Donghui Lu; Meng Xue
Journal:  Purinergic Signal       Date:  2022-03-26       Impact factor: 3.765

2.  Prevalence and mortality of cardiovascular events in patients with hyperthyroidism: a nationwide cohort study in the United States.

Authors:  Mohammad Hussein; Eman Toraih; Adin S C Reisner; Peter Miller; Ralph Corsetti; Emad Kandil
Journal:  Gland Surg       Date:  2021-09

Review 3.  2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.

Authors:  Thanh D Hoang; Derek J Stocker; Eva L Chou; Henry B Burch
Journal:  Endocrinol Metab Clin North Am       Date:  2022-05-11       Impact factor: 4.748

4.  Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy.

Authors:  Alan Chun Hong Lee; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-08-10

Review 5.  Focus on Autoimmune Myocarditis in Graves' Disease: A Case-Based Review.

Authors:  Lujin Wu; Wei Wang; Qianru Leng; Nana Tang; Ning Zhou; Yan Wang; Dao Wen Wang
Journal:  Front Cardiovasc Med       Date:  2021-07-07

6.  The Association between Thyroid-Stimulating Hormone and Long-Term Outcomes in Patients with ST Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention.

Authors:  Yuansong Zhu; Jian Shen; Yuzhou Xue; Zhenxian Xiang; Yi Jiang; Wei Zhou; Suxin Luo
Journal:  Int J Gen Med       Date:  2021-10-02

7.  Thyroid Hormone Therapy and Incident Stroke.

Authors:  Maria Papaleontiou; Deborah A Levine; David Reyes-Gastelum; Sarah T Hawley; Mousumi Banerjee; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

Review 8.  Thyroid hormones in diabetes, cancer, and aging.

Authors:  Benoit R Gauthier; Alejandro Sola-García; María Ángeles Cáliz-Molina; Petra Isabel Lorenzo; Nadia Cobo-Vuilleumier; Vivian Capilla-González; Alejandro Martin-Montalvo
Journal:  Aging Cell       Date:  2020-10-13       Impact factor: 9.304

9.  Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.

Authors:  Eyun Song; Mina Kim; Sojeong Park; Min Jeong Park; Jung A Kim; Eun Roh; Ji Hee Yu; Nam Hoon Kim; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Kyung Mook Choi; Sei Hyun Baik; Hye Jin Yoo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-08       Impact factor: 5.555

10.  Antithyroid Drug Treatment in Graves' Disease.

Authors:  Jae Hoon Chung
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.